• Baxter International Inc., of Deerfield, Ill., presented data at the Alzheimer's Association International Conference in Boston from the Phase III Gammaglobulin Alzheimer's Partnership study showing that, as previously disclosed, the study did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease.